Bertrand Damour

Bertrand Damour serves as the Chief Executive Officer and Board Director of Pheon Therapeutics. He has 20 years of management experience in the biotech industry in Europe and the US as CEO of biotech companies and in the banking industry. He was previously CEO of NBE-Therapeutics, the developer of NBE-002, an anti-ROR1 Antibody-Drug Conjugate (ADC). Boehringer Ingelheim acquired NBE-Therapeutics in early 2020 for US$1.4 billion. Earlier in his career, he was CEO of GeneProt Inc., a US proteomics company; Mind NRG, Swiss biotech in the field of CNS (which was acquired by Minerva Neurosciences (NASDAQ: NERV); OncoEthix, a Swiss-based oncology company in the field of epigenetics, (which was acquired by Merck & Co. (NYSE: MRK) for US$375 million; and more recently at Synthena AG, a company developing Oligonucleotide based therapeutics for the treatment of genetic neuromuscular diseases. Bertrand has extensive expertise in corporate transactions, including M&A, LBOs, and IPOs which he gained while working in the banking industry at J.P. Morgan, Rabobank International, and Deutsche Bank in New York.